Myhas, likely a long non-coding RNA (lncRNA), may play a regulatory role in myosin heavy chain (MHC) gene expression. MHC is crucial for muscle function, and Myhas, as an antisense transcript, could potentially be involved in mechanisms that regulate shifts in MHC gene expression in response to exercise training [3].

In the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS), the progression of Myhas RNA levels across disease stages correlated with longevity. It effectively discriminated between long-and short-term survival individuals, suggesting its potential as a prognostic indicator for ALS [1].

In laryngeal cancer, Myhas appears to be a protective factor. A 4-lncRNA signature including Myhas was developed to predict the prognosis of patients, and functional annotation analysis suggested that the mechanisms may involve extracellular exosome, Notch, voltage-gated calcium channels, and Wnt signaling pathways [2].

In conclusion, Myhas seems to have important functions in both normal muscle-related regulation and disease contexts. In ALS, it shows promise as a prognostic biomarker, and in laryngeal cancer, it may protect against the disease through various signaling pathways. Research on Myhas using animal models like the SOD1G93A mouse model has provided valuable insights into its role in disease processes.